The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in sub-Saharan Africa

Amref Health Africa selected as implementing partner to provide technical assistance for the new peer-to-peer learning network

NAIROBI, Kenya, August 2, 2022 /PRNewswire/ — The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies. Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

The network is already connecting ministry of health officials, implementing partners, and other key actors across Kenya, Malawi, Tanzania, and Uganda through activities designed to take place within and between countries (intra- and cross-country), so participants can share lessons learned and best practices for boosting local demand for Covid-19 vaccines. Plans to expand to other countries in the region are underway as well.

“The Vaccination Action Network’s community-based approach brings together our counterparts from across the region and country. This collaboration is the key to finding and implementing the right vaccination approach,” said Dr. Diana Atwine, Permanent Secretary, Ministry of Health, Uganda. In a recent VAN learning session focused on Wakiso district, Dr. Mathias Lugoloobi, District Health Officer in Uganda’s central Wakiso District echoed this sentiment, saying that “for strategies to be successful, the community alone must have the final say.”

While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses. Inconsistent and inequitable access to supplies initially hindered the continent’s vaccination campaigns. However, uptake is now primarily impacted by complex delivery scenarios, limited access to vaccination centers, and other ongoing demand barriers, such as vaccine hesitancy and waning concerns about Covid-19 infection.

VAN’s objective is to help decision-makers understand the drivers behind vaccination and support initiatives that will increase Covid-19 vaccine uptake, while strengthening routine immunization so that health systems are better equipped to respond when the next pandemic strikes. This reflects The Rockefeller Foundation’s regional commitment to support localized solutions, empower community representatives, and create more resilient health systems.

“The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership,” said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office. “By making these discussions country-led, we want to create a space where those directly involved in vaccination campaigns are able to voice what is working, what isn’t, and what needs to change to improve vaccination rates.”

Peer-to-peer learning is an important tool for officials who are working to address these challenges. Since the start of the Covid-19 pandemic, this type of intra- and inter-country coordination has helped the continent scale up genomic sequencing and secure essential tools, including personal protective equipment and diagnostic tests.

“By encouraging officials to come together, the Vaccination Action Network is opening new dialogues that emphasize regional solutions to local challenges,” said Githinji Gitahi, Group CEO at Amref. “This is essential to tackle vaccine equity issues, which are tied to national and regional contexts, but also offers countries an opportunity for longer-term coordination on other priorities.”

VAN will host monthly intra-country sessions and multiple cross-country discussions before the end of the calendar year, with the goal of turning learnings from these sessions into actionable solutions. To facilitate this, VAN is supporting Amref through a USD$5 million grant to design and implement tailored strategies that better reflect local needs and address demand barriers for increased vaccine uptake.

Prior to the launch, VAN hosted two cross-country and five intra-country discussions, which have already yielded results. Following a May VAN session focused on improving vaccine understanding and uptake, the Infectious Diseases Institute (IDI) at Makerere University in Kampala, Uganda is now working to train “vaccination champions” in the Wakiso district. The goal is for champions to connect with communities about the benefits of vaccines, address their questions and concerns, and ultimately encourage vaccination through community-based strategies that have proved successful in past epidemic control settings in Uganda.

“One of our biggest takeaways from the VAN conversation was that we needed to do more to engage communities with accurate and approachable information on Covid-19 vaccines, leaning on lessons learned from other health challenges such as HIV and Ebola,” said Mohammed Lamorde, Head of Global Health Security at IDI. “That’s why our program focuses on working with trusted community members and leaders to equip them with the tools they need to encourage greater uptake of vaccines within their communities.”

VAN represents the Global Vaccination Initiative (GVI)’s first major investment in overcoming low vaccine demand in Africa. Launched in April 2022, GVI is The Rockefeller Foundation’s USD$55 million effort to support country-led efforts to fully vaccinate 90% of the most at-risk populations in Africa, Asia, Latin America, and the Caribbean over the next two years.

About The Rockefeller Foundation

The Rockefeller Foundation is a pioneering philanthropy built on collaborative partnerships at the frontiers of science, technology, and innovation to enable individuals, families, and communities to flourish. We work to promote the well-being of humanity and make opportunity universal.  Our focus is on scaling renewable energy for all, stimulating economic mobility, and ensuring equitable access to healthy and nutritious food.  For more information, sign up for our newsletter at rockefellerfoundation.org and follow us on Twitter @RockefellerFdn.

Amref Health Africa, headquartered in Kenya, is the largest Africa-based International Non-Governmental Organisation (INGO). With a focus on increasing sustainable health access, Amref runs programmes in over 35 countries in Africa, with lessons learnt over 60 years of engagement with governments, communities, and partners. Amref Health Africa also engages in programme development, fundraising, partnership, advocacy, monitoring and evaluation, and has offices in Europe and North America as well as subsidiaries: Amref Flying Doctors, Amref Enterprises and the Amref International University.

About Dalberg

Dalberg is a leading social impact advisory group that brings together strategy consulting, design thinking, big data analytics, and research to address complex social and environmental challenges. It works collaboratively with communities, institutions, governments, and corporations to develop solutions that create impact at scale. The Dalberg Group is comprised of six businesses: Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Implement, Dalberg Media, and Dalberg Research, and a not-for-profit, Dalberg Catalyst. For more information, visit www.dalberg.com.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

South American countries set to launch official 2030 World Cup bid

MONTEVIDEO— Four South American countries on Tuesday launch an unprecedented joint bid to host the 2030 World Cup with the hope of bringing the global showpiece back to its first home.

Uruguay, Argentina, Paraguay and Chile’s intention to bid has long been in the making.

More than three years ago they committed to create a local organizing committee to co-ordinate with South American football’s governing body CONMEBOL to plan their bid.

But it has taken until now for the “Juntos 2030” (Together 2030) bid to be made official.

It centers on the desire to “bring the World Cup back to its original home: South America,” said CONMEBOL president Alejandro Dominguez.

The very first edition of the World Cup in 1930 was held in Uruguay and won by the hosts, beating their neighbors Argentina 4-2 in the final.

The joint South American bid aims to stage the 2030 final in the very same Centenario stadium that hosted the first title match 100 years earlier.

“For us it should be called the 2030 Centenary World Cup,” said Uruguay’s sports minister Sebastian Bauza.

“What we have to focus on is the Centenary World Cup. The 100 year celebration of the first World Cup will be here. Back to the legend, back to its roots!”

Should it be successful, though, the two tournaments could not be more different.

In 1930 there were only 13 teams and the entire tournament was played in the same city — Montevideo — in just three stadiums.

In 2030 there will be 48 teams with around 15 stadiums used across the four countries.

If successful it would be the first time that as many as four countries host the World Cup.

The 2026 tournament has already been awarded to three countries — Canada, Mexico and the United States.

Despite the Latin American region being one of the worst hit by the coronavirus pandemic, Chile’s sports minister Alexandra Benado insisted in an interview published on Monday that all four countries remain in a position to

host the tournament.

“Our proposal will be austere and sustainable and will meet FIFA’s demands,” Benado told El Mercurio newspaper.

The joint South American bid will likely come up against at least two other proposals.

Spain and Portugal have officially submitted a joint bid while Morocco have repeatedly insisted they will bid to become only the second ever African country to host the finals.

The United Kingdom and Republic of Ireland decided in February to abandon a joint bid that would have seen five FIFA member federations hosting the tournament.

There has also been tentative talk of an Israeli bid alongside the United Arab Emirates and Bahrain.

The last World Cup to be hosted in South America was Brazil 2014.

More than half of the 21 World Cup finals already staged have been in Europe but later this year Qatar will host the finals, only the second time they will be in Asia.

Source: NAM NEWS NETWORK

UN troops in shootout at DR Congo-Uganda border

KINSHASA— Two people have been killed and several injured after UN peacekeepers returning from leave in Uganda opened fire to force their way through a border into eastern Democratic Republic of Congo.

Bintou Keita, the head of the UN peacekeeping mission, has described the troops’ actions as unspeakable and irresponsible.

She said arrests had been made and an investigation opened.

A video shared on social media shows troops in a UN convoy trying to cross the border from Uganda into eastern DR Congo – and an argument can be heard.

Then suddenly there are loud bursts of gunfire from the convoy and people scatter in all directions. The UN troops drive into DR Congo still shooting.

Over the last week there have been violent protests in DR Congo against the UN’s Monusco mission, which many feel has failed to protect people from armed attacks in which 20 people died.

Source: NAM NEWS NETWORK

Update: Uganda monitors DRC border after deadly shooting involving UN peacekeepers

KAMPALA— Ugandan police are deploying a standby force to the border with the Democratic Republic of Congo (DRC) after UN peacekeeping troops opened fire on a border post, killing two people and wounding 15, including an 8-year-old Ugandan girl.

Uganda says it has deployed a team to monitor ongoing tensions in the eastern DRC resulting from a deadly shooting involving MONUSCO soldiers.

The incident that has been described in a statement by the UN Special Representative Bintou Keita as unspeakable and irresponsible happened in the town of Kasindi in the DRC’S Beni territory close to Uganda.

The statement said that during the incident, soldiers from the Intervention Brigade of the MONUSCO force from Tanzania, returning from leave, opened fire at the border post for unexplained reasons and forced their way through.

Fred Enanga, the Uganda Police spokesperson, described the incident.

“So, one of the bullets strayed and hit an eight-year-old juvenile called Bira Jackline,” he said. “She’s getting treatment at Bwera hospital. The stray bullet hit her shoulder and it was retrieved. So, she’s out of danger.”

In his statement, Bintou said the perpetrators of the shooting were identified and arrested pending the conclusions of the investigation, which has already started in collaboration with Congolese authorities.

Bintou added that contact had also been established with Uganda so that legal proceedings can be initiated urgently with the participation of victims and witnesses.

MONUSCO, the peacekeeping mission in the DRC, was in 2010 given the mandate to carry out offensive operations.

In another statement, U.N. Chief Antonio Guterres said he was saddened and outraged by the incident and demanded accountability.

With ongoing tension between DRC locals and MONUSCO, Enanga said authorities are monitoring the situation.

“We’ve been closely monitoring what happened from the other side of Bunagana and DRC,” he said. “We don’t want the violence there to affect our borderline. We have a standby team monitoring.”

Trade between DRC and Uganda slowed down since March due to the resumption of fighting between DRC government forces and M23 rebels who took over the town of Bunagana. Uganda has since March registered 41,164 asylum seekers comprising 21,235 households.

Source: NAM NEWS NETWORK

Africa fights Monkeypox without vaccines as death toll rises: CDC

ADDIS ABABA— The vast majority of deaths due to monkeypox have been registered on the African continent but Africa remains the only part of the world with no doses of the vaccine, according to the Africa Centers for Disease Control and Prevention.

The World Health Organisation declared monkeypox a new global health emergency after 20,000 cases were reported in 77 countries. Some 75 people have died in the 11 African countries where the disease was recorded, the acting head of the African Centre for Disease Control, Ahmed Ogwell has said.

While the disease was already present on the continent in Central and West Africa before the global spread, it was detected in Europe, North America and Asia in May 2022, as it spread.

Monkeypox on the continent was mainly spread to people via infected rodents – while in Europe and North America – people with no links to animals or recent trips to the African continent seem to be contracting the disease.

WHO has stressed that anyone can be infected with monkeypox if they are in close contact with someone with the disease or they touch contaminated clothing or sheets. However, researchers are still looking into how it is spread via skin-to-skin contact.

Both the U.S. and Europe have secured doses after a number of delays; the European Commission reported it has purchased 160,000 vaccines, while the U.S. has obtained some 800,000 doses that will soon be distributed.

Source: NAM NEWS NETWORK

Malaysia, US Value Longstanding Ties, Will Continue Working For Prosperity And Security

KUALA LUMPUR— Malaysia and the United States (US) value their longstanding bilateral ties and will continue working together on economic prosperity and security.

Malaysian Prime Minister Ismail Sabri Yaakob and the US House of Representatives Speaker Nancy Pelosi (picture) said this during a luncheon hosted in honour of the latter at a leading hotel here, Tuesday.

Pelosi and her congressional delegation arrived in Malaysia early Tuesday as part of the official visit to four Asian countries.

Ismail Sabri in his welcoming remarks pointed out that both sides enjoyed good relations in all fields including economy, investment, health and defence.

The prime minister said the partnership was further strengthened and went a notch higher through the recently concluded ASEAN-US Special Summit held in Washington DC from May 12 to 13, which also bought ASEAN closer to the US.

The partnership was also strengthened through vaccine diplomacy cooperation where the US has donated one million doses of the Pfizer-BioNTech Covid-19 vaccines to Malaysia to help the country’s fight against the pandemic.

In defence, the US has extended a lot of assistance so far, including grant assistance worth US$200 million, he said.

“As we all know, Malaysia and the US enjoy good relations and remain important partners in all fields. In economy, the US is the biggest investor in the country,” he said in his speech in Malay at the luncheon meet.

Also in attendance at the event were Malaysian Senior Minister for Defence Hishammuddin Hussein and Foreign Minister Saifuddin Abdullah.

The prime minister thanked Pelosi and her delegation for her maiden visit to Malaysia in an effort to boost bilateral ties between both nations.

Meanwhile, Pelosi said she and her high-powered delegation were willing to learn more from Malaysia and collaborate closely in terms of security and economic prosperity.

“Malaysia is very important. We’ve had over 60 years of relationship between the United States and Malaysia. We value that relationship,” she added.

Kuala Lumpur is Pelosi’s second stop after Singapore on Monday before she heads to South Korea and Japan with her tour being closely watched to see if Taiwan is also on her itinerary.

The Chinese Foreign Ministry had said that in the event of Pelosi’s visit to Taiwan, Beijing will take decisive measures to protect its sovereignty and territorial integrity, and the US will be fully responsible for all the consequences resulting from the visit.

As part of her itinerary here, she paid a courtesy call on Dewan Rakyat (Malaysian Parliament) Speaker Azhar Azizan Harun at the Parliament building at noon.

The US established diplomatic ties with Malaysia in 1957 following the then Malaya’s independence from Britain.

The US is currently Malaysia’s third largest global trade partner and export destination, while Malaysia is the US’ 17th largest trade partner.

Despite the challenging global economy and economic uncertainties following the outbreak of Covid-19, total trade between the two countries increased by 21.4 per cent year-on-year to RM217.10 billion (US$52.37 billion) in 2021.

Source: NAM NEWS NETWORK

Four dead in South Africa protests over high power costs

JOHANNESBURG— At least four people have died during protests over the cost of electricity in a South African township, police officials have said.

On Monday, residents angry at the high cost of basic services barricaded roads with burning tyres and set ablaze a municipal building in Thembisa township, northeast of the financial hub, Johannesburg.

Authorities said two people were killed in alleged police shootings after the protests broke out in the morning.

“It’s alleged they have been shot,” local municipal police spokeswoman Kelebogile Thepa said.

Later in the evening, Thepa said two more bodies had been found near the entrance of the burned building – bringing the total death toll to four.

Police were yet to confirm what caused the deaths, she added. Investigations were under way.

Protests over poor services occur regularly in South Africa, which is battling some of the highest unemployment and crime rates in the world. Power cuts have also become frequent in recent months, as national utility company Eskom battles high debts and a labour strike.

The latest bout of protests came less than two weeks after former President Thabo Mbeki warned the country could see an uprising similar to the Arab Spring, triggered by mounting discontent.

Last month, Mbeki accused President Cyril Ramaphosa of failing to deliver on his promises to tackle widespread poverty, inequality and unemployment, which stands at more than 34.5 percent, with youth joblessness at nearly 64 percent.

The situation has been worsened by the rise of food prices occasioned by disruptions in wheat supply as the Russian invasion of Ukraine continues.

A year ago, South Africa saw an outbreak of the worst violence the country has experienced since the end of the apartheid era three decades ago. The large-scale rioting and looting then left more than 350 dead.

The 10 days of rioting followed the imprisonment of former president Jacob Zuma for snubbing corruption investigators. They happened mainly in KwaZulu-Natal province but also in Gauteng where Johannesburg is located.

Source: NAM NEWS NETWORK

AOP Health Starts Research for Leukemia Treatment

AOP Health signed an agreement with Leukos Biotech for the further development of a newly discovered chemical substance. With this agreement AOP Health expands the hemato-oncology research area even further and provides additional treatment options for certain leukemia patients in the longer term.

Agnes Kohl, Chief Business Officer, AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group

Photo credit: Studio Koekart: Natascha Unkart & Isabelle Köhler

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) — The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care. In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute. The agreement signed by AOP Health covers the option for developments of the newly discovered chemical substance within any treatable indication, not limited to oncological or rare diseases.

Luis Ruiz-Avila, Chief Executive Officer Leukos Biotech

Copyright: Albert Mollon

Agreement sets basis for new areas of therapy

At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Both are special disease types of leukemia that often start in the bone marrow. Agnes Kohl, Chief Business Officer of AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group explains: “Based on positive data, our plan is to expand the development for further orphan indications even outside of AML and MDS at a later stage. With this agreement, we may be able to broaden the portfolio within our therapeutic areas offering even more treatment options for patients.”

Development in cooperation with Leukos

As AOP Health focuses on rare, hemato-oncological cancers and has many years of experience in the development and commercialization of hemato-oncological treatments, the company will drive the further development of the substance in cooperation with Leukos based on a new mode of action. This could potentially turn into a milestone in the treatment of many blood cancer and other cancer patients. Luis Ruiz-Avila, Chief Executive Officer of Leukos Biotech: “We focus on developing new treatments for a wide variety of tumors. We were born to transform excellent science from the Josep Carreras Leukaemia Research Institute into valuable products for cancer patients in need, and this agreement is a very significant step in that direction. We are convinced that AOP Health is the right partner to turn this promising, novel mechanism of action into a clinical reality for the benefit of patients in a wide variety of unmet medical needs”.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all its stakeholders on the other – especially the patients and their families as well as also the healthcare professionals treating them.

About Leukos

Leukos Biotech, SL (Leukos) is a spin-off company from the Josep Carreras Leukaemia Research Institute incorporated in Barcelona in 2015. The company is developing new treatments and diagnostic tools for a wide variety of tumors targeting the serotonin receptor HTR1B, which antitumoral potential was first described and patented by Leukos’ founder Dr. Ruth Risueño in her laboratory at the Josep Carreras Research Institute. Leukos’ main financial support is from private and institutional investors. The main shareholders are Inveready, CDTI Innvierte and the Josep Carreras Foundation. Besides investors’ support, Leukos has received non-dilutive grants and loans from the Catalan Government, the Spanish Government and the European Union in various programs.

About the Josep Carreras Foundation

The Josep Carreras Leukaemia Foundation was established in 1988 with the intention of contributing to finding a definitive cure for this disease. Its efforts are concentrated on four basic areas: administering the Spanish Bone Marrow Donor Registry (REDMO), scientific research, carried out by the Josep Carreras Leukaemia Research Institute, patient guidance through an online patient consultation channel, and reception apartments for patients who need to undergo treatment and have to spend a long time far from home.

About the Josep Carreras Leukaemia Research Institute

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya’s CERCA network, was established in 2010 with the aim of furthering biomedical research and personalised medicine in the field of leukaemia and other onco-hematological diseases. It is the first research centre in Europe exclusively focussed on leukaemia and malignant blood diseases, and one of the very few in the world. The Josep Carreras Institutes has three coordinated but independent scientific campuses: University of Barcelona Hospital Clínic Campus, The Catalan Institute of Oncology/Germans Trias i Pujol Campus, and the Sant Pau – Autonomous University of Barcelona (UAB) Campus

About Inveready

Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 200 active companies, and more than €1bn of assets under management. Inveready has been investing in companies in the Life Sciences sector since 2008. Notable investments in this vertical are Atrys Health (listed on the Spanish market), EDESA Biotech (listed on Nasdaq), AVX Pharma (sold to Aerie Biotech) and PaloBiofarma (licensing agreement with Novartis). Inveready is headquartered in San Sebastian, and has other offices in Barcelona and Madrid. It has been recognized on multiple occasions by ASCRI and Preqin for the return on its funds and transactions (For more information, visit www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Needs. Science. Trust.

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2, 1190 Vienna, Austria
aop-health.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392

AOP Health commence la recherche d’un traitement pour la leucémie

AOP Health a signé un accord avec Leukos Biotech pour la poursuite du développement d’une substance chimique récemment découverte. Avec cet accord, AOP Health élargit encore davantage le domaine de la recherche sur l’hémato-oncologie et propose des options de traitement supplémentaires à certains patients atteints de leucémie sur le long terme.

VIENNE, Autriche, 01 août 2022 (GLOBE NEWSWIRE) — AOP Health Group (AOP Health) est un pionnier européen des thérapies intégrées pour les maladies rares et les soins intensifs basé à Vienne, en Autriche. La société se concentre sur la recherche, le développement et la vente mondiale de solutions de traitement innovantes et se spécialise dans les thérapies pour les maladies rares et les soins intensifs. Début juillet, AOP Health a signé un accord avec Leukos Biotech, une société dérivée fondée par l’institut de recherche sur la leucémie Josep Carreras, basé à Barcelone. L’accord signé par AOP Health couvre l’option de développement de la substance chimique récemment découverte dans le cadre de toute indication traitable, non limitée aux maladies oncologiques ou rares.

L’accord établit la base de nouveaux domaines thérapeutiques

Dans un premier temps, AOP Health se concentrera sur le développement d’options de traitement pour la leucémie myéloïde aiguë (LMA) et le syndrome myélodysplasique (SMD). Les deux sont des types particuliers de leucémie qui commencent souvent dans la moelle osseuse. Agnes Kohl, directrice commerciale d’AOP Orphan Pharmaceuticals GmbH, membre du groupe AOP Health, explique : « Sur la base de données positives, notre plan est d’étendre le développement d’autres indications orphelines même en dehors de la LMA et du SMD à un stade ultérieur. Grâce à cet accord, nous pourrons peut-être élargir le portefeuille de nos domaines thérapeutiques en offrant encore plus d’options de traitement aux patients. »

Développement en coopération avec Leukos

Comme AOP Health se concentre sur les cancers hémato-oncologiques rares et possède de nombreuses années d’expérience dans le développement et la commercialisation de traitements hémato-oncologiques, la société pilotera le développement ultérieur de la substance en coopération avec Leukos sur la base d’un nouveau mode d’action. Cela pourrait potentiellement devenir une étape importante dans le traitement de nombreux cancers du sang et autres patients atteints de cancer. Luis Ruiz-Avila, PDG de Leukos Biotech : « Nous nous concentrons sur le développement de nouveaux traitements pour une grande variété de tumeurs. Nous sommes nés pour transformer l’excellente science de l’Institut de recherche sur la leucémie Josep Carreras en produits précieux pour les patients atteints de cancer dans le besoin, et cet accord est une étape très importante dans cette direction. Nous sommes convaincus qu’AOP Health est le bon partenaire pour transformer ce nouveau mécanisme d’action prometteur en une réalité clinique au profit des patients présentant une grande variété de besoins médicaux non satisfaits. »

À propos d’AOP Health

Le groupe AOP Health comprend plusieurs sociétés, dont AOP Orphan Pharmaceuticals GmbH, dont le siège se trouve à Vienne, en Autriche (« AOP Health »). Le groupe AOP Health est le pionnier européen des thérapies intégrées pour les maladies rares et les soins critiques. Au cours des 25 dernières années, le groupe est devenu un fournisseur établi de solutions de thérapie intégrées opérant depuis son siège social à Vienne, ses filiales et ses bureaux de représentation à travers l’Europe et le Moyen-Orient, ainsi que par l’intermédiaire de partenaires dans le monde entier. Ce développement a été rendu possible par un niveau d’investissement continu élevé dans la recherche et le développement, d’une part, et par une orientation très cohérente et pragmatique vis-à-vis des besoins de toutes ses parties prenantes, d’autre part, en particulier les patients et leurs familles, ainsi que les professionnels de la santé qui les prennent en charge.

À propos de Leukos

Leukos Biotech, SL (Leukos) est une société dérivée de l’Institut de recherche sur la leucémie Josep Carreras, créée à Barcelone en 2015. La société développe de nouveaux traitements et outils de diagnostic pour une large variété de tumeurs ciblant le récepteur de la sérotonine HTR1B, dont le potentiel antitumoral a été décrit pour la première fois et breveté par le Dr Ruth Risueño, fondateur de Leukos dans son laboratoire à l’Institut de recherche Josep Carreras. Le principal soutien financier de Leukos provient d’investisseurs privés et institutionnels. Les principaux actionnaires sont Inveready, CDTI Innvierte et la Fondation Josep Carreras. Outre le soutien des investisseurs, Leukos a reçu des subventions et des prêts non dilutifs du gouvernement catalan, du gouvernement espagnol et de l’Union européenne dans le cadre de divers programmes.

À propos de la Fondation Josep Carreras

La Fondation Josep Carreras Leukaemia a été créée en 1988 dans le but de contribuer à la recherche d’un remède définitif pour cette maladie. Ses efforts se concentrent sur quatre domaines fondamentaux : l’administration du Registre espagnol de donneurs de moelle osseuse (REDMO), la recherche scientifique menée par l’Institut de recherche sur la leucémie Josep Carreras, l’orientation des patients via un canal de consultation des patients en ligne et des appartements d’accueil pour les patients qui ont besoin de subir un traitement et doivent passer beaucoup de temps loin de chez eux.

À propos de l’Institut de recherche sur la leucémie Josep Carreras

L’Institut de recherche sur la leucémie Josep Carreras, centre public appartenant au réseau CERCA de la Generalitat de Catalunya, a été créé en 2010 dans le but de promouvoir la recherche biomédicale et la médecine personnalisée dans le domaine de la leucémie et d’autres maladies onco-hématologiques. Il s’agit du premier centre de recherche européen exclusivement dédié à la leucémie et aux hémopathies malignes, et l’un des rares au monde. Les Instituts Josep Carreras disposent de trois campus scientifiques coordonnés mais indépendants : le Campus clinique de l’Hôpital de l’Université de Barcelone, le Campus de l’Institut catalan d’oncologie/allemands Trias i Pujol et le Campus de Sant Pau – Autonomous University of Barcelona (UAB).

À propos d’Inveready

Inveready est un gestionnaire d’actifs alternatifs de premier plan en Espagne ; il investit dans le capital-risque en phase de démarrage, le capital-risque de croissance, la dette à risque, les actions stratégiques dans des sociétés cotées, les infrastructures et le capital-investissement privé. Il fournit des solutions de financement aux entreprises tout au long de leur cycle de vie. Fondée en 2008, Inveready compte sur 200 sociétés actives et plus d’un milliard d’euros d’actifs sous gestion. Inveready investit dans des entreprises du secteur des sciences de la vie depuis 2008. Les investissements notables dans ce secteur sont Atrys Health (cotée sur le marché espagnol), EDESA Biotech (cotée au Nasdaq), AVX Pharma (vendue à Aerie Biotech) et PaloBiofarma (accord de licence avec Novartis). Le siège social de la société se situe à San Sebastian et elle possède d’autres bureaux à Barcelone et Madrid. La société a été reconnue à plusieurs reprises par l’ASCRI et Preqin pour le rendement de ses fonds et de ses transactions (Pour plus d’informations, veuillez consulter le site www.inveready.com).

Mag Nina Roth, MAS
nina.roth@aop-health.com

AOP Health
Besoins. Science. Confiance.

AOP Orphan Pharmaceuticals GmbH
Membre du groupe AOP Health

Leopold-Ungar-Platz 2, 1190 Vienne, Autriche
aop-health.com

Des photographies accompagnant ce communiqué sont disponibles aux adresses :

https://www.globenewswire.com/NewsRoom/AttachmentNg/f096650f-dbfc-4165-854b-63345d24a713

https://www.globenewswire.com/NewsRoom/AttachmentNg/9aa481fe-91da-4609-8570-2e9a1012c392